The Brussels International Declaration on Lipoprotein(a) Testing and Management

IF 4.9 2区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

Atherosclerosis Pub Date : 2025-05-05 DOI:10.1016/j.atherosclerosis.2025.119218

Florian Kronenberg , Nicola Bedlington , Zanfina Ademi , Marius Geantă , Tobias Silberzahn , Marc Rijken , Aedan Kaal , Mariko Harada-Shiba , Zhenyue Chen , George Thanassoulis , Bogi Eliasen , Jean-Luc Eiselé , Albert Wiegman , Christie M. Ballantyne , Emma Broome , Michele Calabrò , Pablo Corral , Annelies Dol , Leslie J. Donato , Elsie Evans , Magdalena Daccord

{"title":"The Brussels International Declaration on Lipoprotein(a) Testing and Management","authors":"Florian Kronenberg , Nicola Bedlington , Zanfina Ademi , Marius Geantă , Tobias Silberzahn , Marc Rijken , Aedan Kaal , Mariko Harada-Shiba , Zhenyue Chen , George Thanassoulis , Bogi Eliasen , Jean-Luc Eiselé , Albert Wiegman , Christie M. Ballantyne , Emma Broome , Michele Calabrò , Pablo Corral , Annelies Dol , Leslie J. Donato , Elsie Evans , Magdalena Daccord","doi":"10.1016/j.atherosclerosis.2025.119218","DOIUrl":null,"url":null,"abstract":"<div><div>There is striking evidence that a high lipoprotein(a) [Lp(a)] concentration is a strong, independent, and causal cardiovascular risk factor. However, Lp(a) testing rates are very low (1 %–2 %) despite the fact that 1 in 5 individuals have elevated Lp(a) concentrations.</div><div>The Brussels International Declaration on Lp(a) Testing and Management was co-created by the Lp(a) International Task Force and global leaders at the Lp(a) Global Summit, held in Brussels, Belgium, on March 24–25, 2025. The event, organized by FH Europe Foundation, brought together scientific experts, people with the lived experience of elevated Lp(a) and policy makers from the European Institutions and World Health Organization. The World Heart Federation, Global Heart Hub, and European Alliance for Cardiovascular Health and scientific organizations such as European Atherosclerosis Society, and International Atherosclerosis Society were formal partners. The Summit was hosted by a Member of the European Parliament, Romana Jerković, and held under the patronage of the Polish presidency of the Council of the European Union.</div><div>The Declaration calls for 1) integration of Lp(a) testing and management into Global, European and National Cardiovascular Health Plans; 2) appropriate investment, policy and programmes in targeting Lp(a) testing and management based on a recent study demonstrating the substantial overall cost-saving to health systems across the globe; 3) political commitment to mandate systematic Lp(a) testing at least once during a person's lifetime, ideally at an early age, with full reimbursement; 4) incorporation of Lp(a) test results in the context of a person's cardiovascular risk assessment, with development of personalised cardiovascular health roadmaps as needed, without fear of dredit aiscrimination; 5) investment in public and healthcare professional education to increase awareness of Lp(a) and its impact on cardiovascular health.</div></div>","PeriodicalId":8623,"journal":{"name":"Atherosclerosis","volume":"406 ","pages":"Article 119218"},"PeriodicalIF":4.9000,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Atherosclerosis","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0021915025001169","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

There is striking evidence that a high lipoprotein(a) [Lp(a)] concentration is a strong, independent, and causal cardiovascular risk factor. However, Lp(a) testing rates are very low (1 %–2 %) despite the fact that 1 in 5 individuals have elevated Lp(a) concentrations.

The Brussels International Declaration on Lp(a) Testing and Management was co-created by the Lp(a) International Task Force and global leaders at the Lp(a) Global Summit, held in Brussels, Belgium, on March 24–25, 2025. The event, organized by FH Europe Foundation, brought together scientific experts, people with the lived experience of elevated Lp(a) and policy makers from the European Institutions and World Health Organization. The World Heart Federation, Global Heart Hub, and European Alliance for Cardiovascular Health and scientific organizations such as European Atherosclerosis Society, and International Atherosclerosis Society were formal partners. The Summit was hosted by a Member of the European Parliament, Romana Jerković, and held under the patronage of the Polish presidency of the Council of the European Union.

The Declaration calls for 1) integration of Lp(a) testing and management into Global, European and National Cardiovascular Health Plans; 2) appropriate investment, policy and programmes in targeting Lp(a) testing and management based on a recent study demonstrating the substantial overall cost-saving to health systems across the globe; 3) political commitment to mandate systematic Lp(a) testing at least once during a person's lifetime, ideally at an early age, with full reimbursement; 4) incorporation of Lp(a) test results in the context of a person's cardiovascular risk assessment, with development of personalised cardiovascular health roadmaps as needed, without fear of dredit aiscrimination; 5) investment in public and healthcare professional education to increase awareness of Lp(a) and its impact on cardiovascular health.

Abstract Image

查看原文本刊更多论文

关于脂蛋白(a)检测和管理的布鲁塞尔国际宣言

有惊人的证据表明，高脂蛋白(a) [Lp(a)]浓度是一个强大的、独立的、有因果关系的心血管危险因素。然而，Lp(a)检测率非常低（1% - 2%），尽管事实上每5个人中就有1人Lp(a)浓度升高。2025年3月24日至25日，在比利时布鲁塞尔举行的Lp(a)全球峰会上，Lp(a)国际工作组和全球领导人共同制定了《Lp(a)测试和管理布鲁塞尔国际宣言》。该活动由FH欧洲基金会组织，汇集了科学专家、有Lp(a)升高亲身经历的人以及来自欧洲机构和世界卫生组织的决策者。世界心脏联合会、全球心脏中心和欧洲心血管健康联盟以及欧洲动脉粥样硬化学会和国际动脉粥样硬化学会等科学组织是正式合作伙伴。首脑会议由欧洲议会议员罗曼娜·耶尔科维奇主持，并在欧洲联盟理事会轮值主席国波兰的赞助下举行。《宣言》呼吁1)将Lp(a)检测和管理纳入全球、欧洲和国家心血管健康计划；2)根据最近的一项研究表明，针对Lp(a)的检测和管理进行适当的投资、政策和规划，从而为全球卫生系统节省大量总体成本；3)政治承诺要求在一个人的一生中至少进行一次系统性的Lp(a)检测，最好是在年轻时进行，并全额报销；4)将Lp(a)测试结果纳入个人心血管风险评估，并根据需要制定个性化的心血管健康路线图，而不必担心歧视；5)投资于公共和保健专业教育，以提高对Lp(a)的认识及其对心血管健康的影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Atherosclerosis 医学-外周血管病

CiteScore

9.80

自引率

3.80%

发文量

1269

审稿时长

36 days

期刊介绍： Atherosclerosis has an open access mirror journal Atherosclerosis: X, sharing the same aims and scope, editorial team, submission system and rigorous peer review. Atherosclerosis brings together, from all sources, papers concerned with investigation on atherosclerosis, its risk factors and clinical manifestations. Atherosclerosis covers basic and translational, clinical and population research approaches to arterial and vascular biology and disease, as well as their risk factors including: disturbances of lipid and lipoprotein metabolism, diabetes and hypertension, thrombosis, and inflammation. The Editors are interested in original or review papers dealing with the pathogenesis, environmental, genetic and epigenetic basis, diagnosis or treatment of atherosclerosis and related diseases as well as their risk factors.